Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081015 · ClinicalTrials.gov registry record
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 1,494
- Enrollment target
NCT01081015: Completed study, sponsored by Celgene.
NCT01081015 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 1,494 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01081015 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 1,494 participants
- Enrollment target
Study Summary
The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.
Primary Outcome
The primary objective is to 1) describe practice patterns of first line therapy regimens and subsequent therapeutic strategies in patients initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting (2) Provide insight into therapeutic regimens and therapy sequence in clinical practice as they relate to clinical outcomes in patients initiated on first-line, second-line or subsequent therapies for CLL.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,494 participants |
| Start Date | 2010-03-19 |
| Est. Completion | 2017-12-31 |
What the finished NCT01081015 record still lists
NCT01081015 is an observational study that tracks outcomes without assigning an intervention. Its 1,494 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01081015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01081015 about?
NCT01081015 is a clinical study titled "Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry". The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employ...
What is the current status of trial NCT01081015?
This trial is currently completed. The enrollment target is 1,494 participants. The study started on 2010-03-19. Estimated completion is 2017-12-31.
Who is sponsoring clinical trial NCT01081015?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI